iSpecimen

iSpecimen EBIT Growth

The Year-over-Year EBIT Growth of iSpecimen (ISPC) as of Nov 5, 2026 is 29.46 %. In the previous year, Year-over-Year EBIT Growth was -13.96 % — a change of -311.13% (higher).

EBIT Growth

29.46 %

YoY

-311.13%

Last updated:

Year-over-Year EBIT Growth of iSpecimen is 2025 29.46 % . Year-over-Year EBIT Growth of iSpecimen was 2024 -13.96 % . It decreases by -311.13% higher compared to the previous year.

The iSpecimen EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2019
25.80 USD
Jan 1, 2020
19.13 USD
Jan 1, 2021
-168.38 USD
Jan 1, 2022
-48.36 USD
Jan 1, 2023
-9.76 USD
Jan 1, 2024
-13.96 USD
Jan 1, 2025
29.46 USD
The iSpecimen EBIT Growth history
YEAREBIT GrowthYoY
29.46 %-311.13%
-13.96 %+43.01%
-9.76 %-79.82%
-48.36 %-71.28%
-168.38 %-980.27%
19.13 %-25.86%
25.80 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

iSpecimen Stock analysis

What does iSpecimen do? iSpecimen, Inc. generates revenue through its iSpecimen Marketplace platform, which connects healthcare providers with biospecimens to researchers in biopharmaceutical, in vitro diagnostic (IVD), and government/academic sectors. The platform consolidates biospecimen procurement by offering a single online marketplace where healthcare supply partners provide de-identified healthcare data, enabling researchers to search, manage workflows, and access administrative tools. Biopharmaceutical companies, IVD firms, and academic institutions purchase access to the platform’s data and services to accelerate medical discovery and streamline procurement processes. The company’s functional areas—search, workflow, data, and administration and reporting—support these transactions through integrated administrative and compliance management for all users. The iSpecimen Marketplace platform serves biopharmaceutical companies, in vitro diagnostic (IVD) companies, and government/academic institutions by providing a centralized hub for biospecimen procurement. Healthcare providers supplying biospecimens use the platform to list their collections, while researchers from the target sectors access the data for their studies. The platform’s de-identified healthcare data, compiled from healthcare supply partners, is a key asset that drives transactions. Administrative and reporting functions within the platform streamline operations for both suppliers and researchers, reducing manual effort and improving compliance. iSpecimen, Inc. monetizes its platform by facilitating connections between biospecimen suppliers and researchers across biopharmaceutical, IVD, and academic sectors. The company’s revenue comes from transactions and services provided through the iSpecimen Marketplace, which includes search capabilities, workflow management, data access, and administrative support. Healthcare supply partners contribute de-identified healthcare data to the platform, which researchers use to identify and procure necessary biospecimens for medical research and development. iSpecimen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about iSpecimen stock

Year-over-Year EBIT Growth of iSpecimen is 29.46 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth iSpecimen since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's iSpecimen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — iSpecimen

All Key Metrics — iSpecimen